Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Coalition for Epidemic Preparedness Innovations (CEPI) | UNKNOWN |
| Instituto Nacional de Saúde, Mozambique | OTHER_GOV |
| University of Antananarivo | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Three complementary activities will be implemented:1) Baseline and repeat census of the catchment population; described in a separate protocol (IVI-ECOVA-03-WS1); 2) Enhanced surveillance for COVID-19 disease, and 3) AEFI-enhanced surveillance. The mass vaccination campaign will be conducted by the Government and is not part of this protocol.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Case |
| ||
| Test Negative Control |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sinopharm Vaccine | Other | Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign |
|
| Measure | Description | Time Frame |
|---|---|---|
| Protection conferred by two completed doses of Sinopharm vaccine against confirmed COVID-19 disease | Protection conferred by two completed doses of Sinopharm vaccine against RT-PCR-confirmed COVID-19 disease measured as the reduction in risk in adults who received two completed doses of the vaccine compared to those who are not vaccinated. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate the effectiveness of two completed doses of the Sinopharm vaccine against severe SARS-CoV-2 infection | Evaluate the effectiveness of two completed doses of the Sinopharm vaccine against RT-PCR confirmed severe SARS-CoV-2 infection | 2 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study will be conducted in the Dondo District. For surveillance the catchment area will include participants from Dondo Sede and Mafambisse administrative posts. The participant will come for screening in the following health facilities; Dondo, Baptista, Mandruzi, Canhandula, Samora Machel) and in Mafambisse (Mafambisse and Bloco Nove) and at the community level, the study will involve walk-throughs for COVID-19 testing.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Florian Marks, PhD | Contact | +821087033813 | fmarks@ivi.int | |
| Birkneh Tilahun Tadesse, PhD | Contact | +821098041348 | birkneh.tadesse@ivi.int |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dondo Health Facility | Recruiting | Dondo | 2104 | Mozambique |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| International Centre for Diarrhoeal Disease Research, Bangladesh |
| OTHER |
| Harvard University | OTHER |
| Heidelberg University | OTHER |
Not provided
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |